Clinical trials: Renal Transplant Recipient
Kidney Failure, Chronic, Covid19
Assessment of Immune Response After Vaccination Against COVID-19 in Patients Treated With Renal Replacement Therapy
Chronically dialyzed patients and kidney transplant recipients have been identified as particularly vulnerable to SARS-CoV-2 infection due to unavoidable exposure.
- Conditions
- Kidney Failure, Chronic, Covid19, Vaccine Reaction, Vaccine Adverse Reaction
- Trial name
- COViNEPH-1 (NCT04905862)
- Testing
- Immune response, Solicited common and expected adverse reactions shortly following vaccination (reactogenicity), use of antipyretic or pain medications and unsolicited adverse events and serious adverse events
- Where
- 4 sites in Poland
- Volunteers
- 180 people
- Sponsor
- Medical University of Gdansk
Renal Transplantation, Gastrointestinal Problems
Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)
The purpose of this study is to assess whether a switch from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI- and/or health-related quality of life outcomes, and to determine the…
- Trial name
- NCT00149968
- Testing
- Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 196 people
- Sponsor
- Novartis
Kidney Transplantation
Standard Induction With Basiliximab Versus No-Induction in Low Immunological Risk Kidney Transplant Recipients
Background: Induction therapy with IL-2 receptor antagonist (IL2-RA) is recommended as a first line agent in low immunological risk kidney transplant recipients.
- Trial name
- NCT04404127
- Testing
- Basiliximab 20 milligram [Simulect], Normal Saline
- Where
- Saudi Arabia
- Volunteers
- 140 people
- Sponsor
- King Faisal Specialist Hospital & Research Center
Renal Transplantation
This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.
This extension study is designed to provide long-term safety and efficacy data beyond 12 months up to Month 36.
- Trial name
- NCT00531440
- Testing
- Everolimus (RAD001)
- Where
- Switzerland
- Volunteers
- 256 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplant
Effects of Personalized Physical Rehabilitation in Kidney Transplant Recipients
This randomized controlled trial (RCT) will examine the effect of a novel 12 month personalized exercise rehabilitation program compared to standard care following kidney transplantation.
- Trial name
- NCT02409901
- Testing
- Exercise Rehabilitation
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- University of Illinois Chicago
Urinary Tract Infection, Asymptomatic Bacteriuria
Perioperative Fosfomycin in the Prophylaxis of Urinary Tract Infection in Kidney Transplant Recipients
A clinical controlled, randomized and double blind trial that included adult patients (≥18 years) receiving kidney transplantation (KT) at the INCMNSZ.
- Trial name
- PERIFOS (NCT03235947)
- Testing
- Fosfomycin disodium, Trimethoprim / Sulfamethoxazole
- Where
- Mexico
- Volunteers
- 82 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Kidney Diseases
Practical Use of Advagraf de Novo After Kidney Transplantation According to Recipient Genetic Polymorphism
To optimize the Advagraf (tacrolimus once a day) initial daily dose used in de novo after kidney transplantation in combination with MMF (or MPA) and corticosteroids (CS) regarding of the genetic Cyp 450 3A5 polymorphism of the…
- Trial name
- CYRANO (NCT02311010)
- Testing
- Advagraf
- Where
- Belgium
- Volunteers
- 150 people
- Sponsor
- Université Catholique de Louvain
BK Virus Infection, Kidney Transplant; Complications
Immune Registry for BK in Kidney Transplant Recipients
Kidney transplantation (KT) is the best treatment modality available to date for patients with advanced kidney disease and the success of KT is dependent on maintaining a selective intricate balance between the risk of rejection…
- Trial name
- NCT06538961
- Testing
- Blood samples: Main Study group, Data Collection, Urine Sample- Main Study group
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Virginia Commonwealth University
Kidney Transplantation
Regimen Optimization Study
Patients who undergo a kidney transplant require prolonged therapy with drugs that suppress the immune system (called immunosuppressive regimens) to stop the immune system from attacking the transplanted kidney in order to limit…
- Trial name
- NCT02137239
- Testing
- Thymoglobulin, Belatacept, mycophenolate mofetil(MMF)
- Where
- 20 sites in United States, Argentina
- Volunteers
- 58 people
- Sponsor
- Bristol-Myers Squibb
Human Influenza
Clinical Trial for the Evaluation of Three Regimens of Influenza Vaccination in Kidney Transplant Recipients
This will be an open label, parallel, randomized clinical trial that will evaluate the immunogenicity and safety of the trivalent influenza vaccine (inactivated and fragmented) produced by Instituto Butantan among adult kidney…
- Trial name
- NCT02104869
- Testing
- Trivalent influenza vaccine (inactivated and fragmented).
- Where
- Brazil
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Immunocompromised Host, Organ Transplantation
Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
Background: Solid organ transplantation provides life-saving treatment for end-stage organ disease but is associated with an increased cancer risk because of the need for long-term immunosuppression End-stage renal disease…
- Conditions
- Immunocompromised Host, Organ Transplantation, Cancer
- Trial name
- NCT00904579
- Where
- 9 sites in United States
- Volunteers
- 19,929,901 people
- Sponsor
- National Cancer Institute (NCI)
Respiratory Syncytial Virus Infections
A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of the RSVPreF3 OA investigational vaccine in an immunocompromised (lung and renal transplant recipients) population and assess whether a…
- Trial name
- RSV OA=ADJ-023 (NCT05921903)
- Testing
- RSVPreF3 OA Investigational Vaccine
- Where
- 46 sites in United States, Australia and 6 more
- Volunteers
- 386 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Graft Rejection, Kidney Failure
Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients
The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal…
- Trial name
- NCT00369382
- Testing
- cyclosporine or tacrolimus, sirolimus
- Where
- 23 sites in United States, Australia and 5 more
- Volunteers
- 121 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Cardiac Surgery, Cardiopulmonary Bypass
REnal TRansplant Outcomes After CARdiac Surgery (RETROCAR)
In this retrospective study, the authors assess long term renal outcome in renal transplant recipients after cardiac surgery with cardiopulmonary bypass, and research factors associated with poor long term renal outcome.
- Conditions
- Cardiac Surgery, Cardiopulmonary Bypass, Renal Transplant Recipient
- Trial name
- RETROCAR (NCT04979754)
- Testing
- standard of care
- Where
- France
- Volunteers
- 93 people
- Sponsor
- University Hospital, Bordeaux
End Stage Renal Disease, Kidney Transplant
A Pilot Study Using Autologous Regulatory T Cell Infusion Zortress (Everolimus) in Renal Transplant Recipients
This study will enroll individuals who have end stage renal disease and who are undergoing a solitary kidney transplant. This study is investigating/evaluating the safety and effectiveness of collecting, expanding and infusing a…
- Trial name
- NCT03284242
- Testing
- Treg
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roberto Gedaly
Kidney Transplantation Recipients
Assessment of CMV-specific ELISPOT Assay for Predicting CMV Infection in Kidney Transplant Recipients
CMV is one of the most important opportunistic infection in transplant recipients. In South Korea, more than 95% of adults reveal sero-positivity for CMV IgG.
- Trial name
- ACE-KT (NCT02025335)
- Where
- South Korea
- Volunteers
- 199 people
- Sponsor
- Asan Medical Center
Transplant Complication, CMV
Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients
The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV infections in kidney transplant…
- Trial name
- NCT06034925
- Testing
- Maribavir, Valganciclovir
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Medical University of South Carolina
Renal Transplantation
Evaluation of the Efficacy of Dd-cfDNA in Routine Patient Care in Kidney Transplant Recipients"
The investigator hypothesizes that the combined use of (1) Donor-derived cell-free DNA (dd-cfDNA) in peripheral blood predicting anti-donor immunological activation or quiescence (2) interactive and actionable data analytics…
- Trial name
- AI-CARE (NCT06406179)
- Testing
- dd-cfDNA-guided
- Where
- 6 sites in France
- Volunteers
- 529 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ischemia
Renal Graft Function After Treatment With Erythropoietin (EPO)
Background : Numerous studies have outlined the cellular pleiotropic effects of erythropoietin (EPO) and their role in the prevention of ischemic-reperfusion lesion such as after acute ischemic injury of the brain or the heart.
- Trial name
- FRETEP (NCT01450878)
- Testing
- beta-epoietin
- Where
- 18 sites in France
- Volunteers
- 6 people
- Sponsor
- University Hospital, Limoges
Renal Transplant Recipients, Elderly Patients
RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients
Open label, randomized, multicenter, intervention trial comparing standard immunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen in combination with everolimus.
- Conditions
- Renal Transplant Recipients, Elderly Patients, Immunosuppression
- Trial name
- OPTIMIZE (NCT03797196)
- Testing
- low dose tacrolimus in combination with everolimus, standard dose tacrolimus with mycophenolate mofetil
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 374 people
- Sponsor
- University Medical Center Groningen